[1]
|
[1]ELSERAG HB AND RUDOLPH KL. Hepatocellular carcinoma:epidemiology and molecular carcinogenesis[J].Gastroenterology, 2007, 132 (7) :2557-2576
|
[2]
|
[2]RAOUL J L, SANGRO B, FORNER A, et al. Evolving strategies for the management of intermediate-stage hepatocellular carcinoma:available evidence and expert opinion on the use of transarterial chemoembolization[J].Cancer Treat Rev, 2011, 37 (3) :212-231.
|
[3]
|
[3]LLOVET JM, BRUIX J. Systematic review of randomized trials for unresectable hepatocellular carcinoma:chemoembolization improves survival[J]. Hepatology, 2003, 37 (2) :429-442.
|
[4]
|
[4]BURREL M, REIG M, FORNER A, et al. Survival of patients with hepatocellular carcinoma treated by transarterialchemoembolisation (TACE) using Drug Eluting Beads. Implications for clinical practice and trial design[J]. J Hepatol, 2012, 56 (6) :1330-1335.
|
[5]
|
[5]SALEM R, LEWANDOWSKI R J, MULCAHY M F, et al.Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres:a comprehensive report of long-term outcomes[J]. Gastroenterology, 2010, 138 (1) :52-64.
|
[6]
|
[6]FARAZI P A, DEPINHO R A. Hepatocellular carcinoma pathogenesis:from genes to environment[J]. Nature Reviews Cancer, 2006, 6 (9) :674-687.
|
[7]
|
[7]BRUIX J, RAOUL J-L, SHERMAN M, et al. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma:subanalyses of a phase III trial[J]. J Hepatol, 2012, 57 (4) :821-829.
|
[8]
|
[8]MALAGARI K, CHATZIMICHAEL K, ALEXOPOULOU E, et al. Transarterial chemoembolization of unresectable hepatocellular carcinoma with drug eluting beads:results of an open-label study of 62 patients[J]. Cardiovasc Intervent Radiol, 2008, 31 (2) :269-280.
|
[9]
|
[9]LLOVET J M, REAL M I, MONTA A X, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma:a randomised controlled trial[J]. The Lancet, 2002, 359 (9319) :1734-1739.
|
[10]袁维国.肝细胞肝癌肝切除术前TACE对预后影响的Meta分析[J].中国肿瘤外科杂志, 2010, 02 (5) :282-287.
|
[11]杨可立, 陈锦滨, 朱应钦, 等.炎症预后评分与肝癌射频消融术预后的相关性[J].广东医学, 2018, 39 (15) :2294-2299.
|
[12]张劲夫, 范正军, 梁润威, 等.术前SIRI和PLR对肝癌切除术后病人生存预测价值分析[J].中国实用外科杂志, 2018, 38 (2) :210-218.
|
[13]何朝滨, 林小军.中性粒细胞/淋巴细胞比值血小板/淋巴细胞比值与TACE治疗肝癌患者预后的相关性[J].中国肿瘤临床, 2017, 44 (6) :283-288.
|
[14]郑游冰, 赵炜, 刘冰, 等.中性粒细胞-淋巴细胞比值预测肝细胞癌患者TACE术后预后[J].中国介入影像与治疗学, 2013, 10 (9) :523-526.
|
[15]张溪.影响BCLC C期肝细胞肝癌患者行TACE治疗预后因素的分析[D].上海:复旦大学, 2013.
|